Welcome to the UPF Digital Repository

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date



Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Thumbnail
Document Type: Article
Version: Published version
Date: 2019
This document is associated with a Creative Common license Copyright © 2019 Remon et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking